{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T22:59:39Z","timestamp":1788303579358,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jaci.2024.12.1085","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T16:58:15Z","timestamp":1736269095000},"page":"1299-1309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Mepolizumab in patients with lymphoid-variant hypereosinophilic syndrome: A\u00a0multicenter prospective study"],"prefix":"10.1016","volume":"155","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8825-8126","authenticated-orcid":false,"given":"Julien","family":"Catherine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Dewispelaere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Lelubre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliane","family":"Schanden\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Roufosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2024.12.1085_bib1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/all.15544","article-title":"Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes","volume":"78","author":"Valent","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2024.12.1085_bib2","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.3389\/fimmu.2020.01765","article-title":"Eosinophilia associated with CD3\u2212CD4+ T cells: characterization and outcome of a single-center cohort of 26 patients","volume":"11","author":"Carpentier","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2024.12.1085_bib3","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1067\/mai.2002.127003","article-title":"High serum thymus and activation-regulated chemokine levels in the lymphocytic variant of the hypereosinophilic syndrome","volume":"110","author":"de Lavareille","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.12.1085_bib4","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jaip.2017.06.006","article-title":"Hypereosinophilic syndrome subtype predicts responsiveness to glucocorticoids","volume":"6","author":"Khoury","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2024.12.1085_bib5","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jaci.2020.08.037","article-title":"Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a phase III, randomized, placebo-controlled trial","volume":"146","author":"Roufosse","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.12.1085_bib6","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jaci.2010.06.049","article-title":"Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome","volume":"126","author":"Roufosse","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.12.1085_bib7","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/j.jaip.2018.04.033","article-title":"Long-term clinical outcomes of high-dose mepolizumab treatment for hypereosinophilic syndrome","volume":"6","author":"Kuang","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2024.12.1085_bib8","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1016\/j.jaip.2021.07.050","article-title":"Safety and efficacy of mepolizumab in hypereosinophilic syndrome: an open-label extension study","volume":"9","author":"Gleich","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2024.12.1085_bib9","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1016\/j.jaip.2021.01.030","article-title":"CD3\u2212CD4+ lymphocytic variant hypereosinophilic syndrome: diagnostic tools revisited","volume":"9","author":"Carpentier","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2024.12.1085_bib10","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa070812","article-title":"Treatment of patients with the hypereosinophilic syndrome with mepolizumab","volume":"358","author":"Rothenberg","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2024.12.1085_bib11","doi-asserted-by":"crossref","DOI":"10.1093\/jleuko\/qiae051","article-title":"Biologic therapy in rare eosinophil-associated disorders: remaining questions and translational research opportunities","author":"Khoury","year":"2024","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jaci.2024.12.1085_bib12","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/MD.0000000000000088","article-title":"The lymphoid variant of hypereosinophilic syndrome: study of 21 patients with CD3\u2212CD4+ aberrant T-cell phenotype","volume":"93","author":"Lefevre","year":"2014","journal-title":"Medicine"},{"key":"10.1016\/j.jaci.2024.12.1085_bib13","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00281-021-00857-w","article-title":"What does elevated TARC\/CCL17 expression tell us about eosinophilic disorders?","volume":"43","author":"Catherine","year":"2021","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.jaci.2024.12.1085_bib14","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJM199910073411503","article-title":"Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia","volume":"341","author":"Simon","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2024.12.1085_bib15","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/eji.1830210525","article-title":"Human eosinophils from hypereosinophilic patients spontaneously express the p55 but not the p75 interleukin 2 receptor subunit","volume":"21","author":"Plumas","year":"1991","journal-title":"Eur J Immunol"},{"issue":"9842","key":"10.1016\/j.jaci.2024.12.1085_bib16","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2024.12.1085_bib17","doi-asserted-by":"crossref","DOI":"10.1093\/jleuko\/qiae152","article-title":"Hypereosinophilic syndrome response to mepolizumab in the setting of a compassionate use program","author":"Coussement","year":"2024","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jaci.2024.12.1085_bib18","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJMoa1812185","article-title":"Benralizumab for PDGFRA-negative hypereosinophilic syndrome","volume":"380","author":"Kuang","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2024.12.1085_bib19","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaip.2022.02.006","article-title":"An international, retrospective study of off-label biologic use in the treatment of hypereosinophilic syndromes","volume":"10","author":"Chen","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2024.12.1085_bib20","first-page":"215","article-title":"Korean adolescent patient with manifestations of lymphocyte variant hypereosinophilic syndrome and episodic angioedema with eosinophilia, treated with reslizumab","volume":"21","author":"Jue","year":"2022","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2024.12.1085_bib21","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1479-5876-11-112","article-title":"Eosinophils affect functions of in\u00a0vitro\u2013activated human CD3\u2212CD4+ T cells","volume":"11","author":"Harfi","year":"2013","journal-title":"J Transl Med"},{"key":"10.1016\/j.jaci.2024.12.1085_bib22","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jaci.2012.07.055","article-title":"Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes","volume":"131","author":"Roufosse","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.12.1085_bib23","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.3109\/10428194.2014.976823","article-title":"Lymphocytic variant hypereosinophilic syndrome progressing to angioimmunoblastic T-cell lymphoma","volume":"56","author":"Roufosse","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jaci.2024.12.1085_bib24","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.jaip.2022.04.037","article-title":"Mepolizumab reduces hypereosinophilic syndrome flares irrespective of blood eosinophil count and interleukin-5","volume":"10","author":"Rothenberg","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2024.12.1085_bib25","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.jaci.2008.02.033","article-title":"Anti\u2013IL-5 (mepolizumab) therapy reduces eosinophil activation ex\u00a0vivo and increases IL-5 and IL-5 receptor levels","volume":"121","author":"Stein","year":"2008","journal-title":"J Allergy Clin Immunol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009167492500003X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009167492500003X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T11:48:10Z","timestamp":1744026490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009167492500003X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S009167492500003X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2024.12.1085","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mepolizumab in patients with lymphoid-variant hypereosinophilic syndrome: A\u00a0multicenter prospective study","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2024.12.1085","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}